From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India
The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.
Sudarshan Pharma Industries Limited (SPIL) informed you that the company has received the certificate of Recognition One Star Export House from the Directorate General of Foreign Trade of the Department of Commerce, Ministry of Commerce and Industry, Government of India, and the same shall be valid for a period of 5 years effective from May 8, 2025 up to March 31,2O28.
Earlier, the company acquired 100% of Cibachem General Trading L.L.C., a Dubai-based entity. This acquisition, for Rs 55,00,000 (or UAE Dirham equivalent), involves 300 shares, each with a face value of AED 1,000. Previously held by the Thakkar family, the deal is subject to Reserve Bank of India approval and is expected to close by September 30, 2025. This strategic move aims to expand Sudarshan Pharma's customer base in the Middle East. Cibachem, established in 2013, operates in general trading, with turnovers of AED 4,99,250 in 2024, AED 3,51,050 in 2023, and AED 4,92,588 in 2022.
About the Company
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. SPIL caters to a wide range of institutions and healthcare organisations operating across diverse segments, including specialty chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
According to the half-yearly results, the net sales increased by 19 per cent to Rs 277 crore and net profit increased by 43 per cent to Rs 7 crore in H2FY25 compared to H2FY24. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24. The company has a market cap of Rs 731 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The company is aiming to increase their profit margin when it resells Active Pharmaceutical Ingredients (API) within India. This strategy led to a notable increase in their EBITDA margin in the second half of the financial year 2025 (H2FY25), which resulted in a substantial growth in their Profit After Tax (PAT) for the same period.
The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 6.27 per share. On November 22, 2024, the shares of the company ex-traded sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up. In March 2025, FIIs bought 1,29,48,000 shares and increased their stake to 18.45 per cent compared to September 2024. The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.
Disclaimer: The article is for informational purposes only and not investment advice.